Produktbild: Data Monitoring in Clinical Trials

Data Monitoring in Clinical Trials A Case Studies Approach

90,94 €

inkl. gesetzl. MwSt.

Beschreibung

Produktdetails

Format

PDF

Kopierschutz

Nein

Family Sharing

Nein

Text-to-Speech

Nein

Erscheinungsdatum

22.06.2006

Herausgeber

David L. DeMets + weitere

Verlag

Springer New York

Seitenzahl

374 (Printausgabe)

Dateigröße

2576 KB

Sprache

Englisch

EAN

9780387301075

Beschreibung

Rezension

From the reviews:

"This book is a must-read for individuals serving on or supporting data monitoring committees as well as statisticians and other disciplines involved in the design and analysis of clinical trials with interim monitoring." Journal of Biopharmaceutical Sciences, Issue 6, 2006

"This edited book gives a brief introduction to data-monitoring committees for clinical trials … . It has been my experience that many persons asked to serve on data-monitoring committees have scientific or clinical expertise relevant to the trial, but have little or no understanding of the purpose of the data-monitoring committee … . Such individuals would greatly benefit from reading this book prior to serving on a data-monitoring committee, as would anyone wishing to gain some insight into the responsibilities and challenges facing data-monitoring committees." (S. W. Lagakos, Short Book Reviews, Vol. 26 (1), 2006)

"The chapters are clearly written, and the take-home lessons are apparent. The 70 contributing authors represent a full range of perspectives on data monitoring and give balanace to the exposition. ...In summary, the book achieves its goal and deserves a place in every medical school's library." (J. Wade Davis, Journal of the American Statistical Association, Vol. 102, No. 477, 2007)

"This book is highly recommended for anyone who starts to serve on a DMC or is already a member of such a board, and also for people in academia, industry, and regulatory agencies as well as for students in biostatistics, epidemiology, clinical trails, and medical ethics." Iris Pigeot, Biometrics, December 2006)

"This book illustrates the complexity of data monitoring processes through a series of case studies presented by many distinguished clinical trial experts. … A total of 29 case studies have been discussed. … This book would be quite useful for the researchers, investigators and individuals serving on the DMC, or planning to do so, who would like to understand the application of data monitoring principles in clinical trials. I have thoroughly enjoyed reading this book and I think it has served its purpose … ." (Faisel Yunus, Journal of Applied Statistics, Vol. 35 (5), 2007)

Produktdetails

Format

PDF

eBooks im PDF-Format haben eine festgelegte Seitengröße und eignen sich daher nur bedingt zum Lesen auf einem tolino eReader oder Smartphone. Für den vollen Lesegenuss empfehlen wir Ihnen bei PDF-eBooks die Verwendung eines Tablets oder Computers.

Kopierschutz

Nein

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie, allen sonstigen eReadern und am PC lesen. Das eBook ist nicht kopiergeschützt und kann ein personalisiertes Wasserzeichen enthalten. Weitere Hinweise zum Lesen von eBooks mit einem personalisierten Wasserzeichen finden Sie unter Hilfe/Downloads.

Family Sharing

Nein

Mit Family Sharing können Sie eBooks innerhalb Ihrer Familie (max. sechs Mitglieder im gleichen Haushalt) teilen. Sie entscheiden selbst, welches Buch Sie mit welchem Familienmitglied teilen möchten. Auch das parallele Lesen durch verschiedene Familienmitglieder ist durch Family Sharing möglich. Um eBooks zu teilen oder geteilt zu bekommen, muss jedes Familienmitglied ein Konto bei Thalia oder einem anderen tolino-Buchhändler haben. Weitere Informationen finden Sie unter Hilfe/Family-Sharing.

Text-to-Speech

Nein

Bedeutet Ihnen Stimme mehr als Text? Mit der Funktion Text-to-Speech können Sie sich im tolino webReader und in der aktuellen Thalia – Lesen & Hören App das eBook vorlesen lassen. Weitere Informationen finden Sie unter Hilfe/Text-to-Speech.

Barrierefreiheit

  • keine Information zur Barrierefreiheit bekannt

Erscheinungsdatum

22.06.2006

Herausgeber

Verlag

Springer New York

Seitenzahl

374 (Printausgabe)

Dateigröße

2576 KB

Sprache

Englisch

EAN

9780387301075

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Weitere Artikel finden Sie in

  • Produktbild: Data Monitoring in Clinical Trials
  • Monitoring Committees: Why and How-David L. DeMets, Curt D. Furberg, Lawrence M. Friedman .-Lessons Learned-David L. DeMets .- FDA Perspective-Susan S. Ellenberg and Jay P. Siegel.- Introduction-Lawrence M. Friedman .- Assessing Possible Late Treatment Effects Early- The Diabetic Retinopathy Study Experience-Fred Ederer .- Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial- Early Experiences in Formal Monitoring Methods-Lawrence M. Friedman, David L. DeMets and Robert Hardy .- Data Monitoring for the Aspirin Component of the Physicians Health Study- Importance of Secondary Outcomes-David L. DeMets and Charles H. Hennekens .- Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial- Protecting Participant Interests in the Face of Scientific Uncertainties and the Cruel Play of Chance-Robert G. Hart, Lesly A. Pearce, Ruth McBride and Richard A. Kronmal .- Early Termination of the Diabetes Control and Complications Trial - Methodologic Issues-John M Lachin, Patricia Cleary, Oscar Crofford, Saul Genuth, David Nathan, Charles Clark, Frederick Ferris, and Carolyn Sieberg for the DCCT Research Group .- Data Monitoring in the AIDS Clinical Trials Group Study #981- Conflicting Interim Results-Dianne Finkelstein .- Challenges in Monitoring the Breast Cancer Prevention Trial-Carol K. Redmond,Joseph P. Costantino andTheodore Colton .- Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure- Potentially High Risk Treatment in High Risk Patients-Jan Feyzi, Desmond Julian, John Wikstrand and Hans Wedel .- Stopping the Randomized Aldactone Evaluation Study Early for Efficacy-Janet Wittes, Jean-Pierre Boissel, Curt Furberg, Desmond Julian, Henri Kulbertus and Stuart Pocock .- Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trials- Avoiding Important Information Loss-Janice Pogue, David Sackett, George Wyse and SalimYusuf .- Data Monitoring in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program-Stuart Pocock, Duolao Wang,Lars Wilhelmsen andCharles Hennekens .- Intro-Curt D. Furberg .- Breaking New Ground - Data Monitoring in the Coronary Drug Project-Paul L. Canner .- Data Monitoring in the Cardiac Arrhythmia Suppression Trial - The Need to Be Prepared Early-David L. DeMets and Lawrence M. Friedman .- Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation Trial- Dealing with an Agonizing Trend-Susan Anderson, Robert Cody, Milton Packer andRichard Schwarz .- Stopping the Carotene and Retinol Efficacy Trial - The Viewpoint of the Safety and Endpoint Monitoring Committee-Anthony B. Miller, Julie Buring and O. Dale Williams .- Monitoring a Clinical Trial with Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post - Traumatic Shock-Roger L. Lewis and Norman Fost .- Challenges in Monitoring the Heart and Estrogen/progestin Replacement Study-Stephen B. Hulley,Deborah Grady, Eric Vittinghoff and O. Dale Williams .- Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial- Early Termination of the Doxazosin Arm-Barry R. Davis and Jeffrey A. Cutler .- Data Monitoring in the Moxonidone Congestive Heart Failure Trial-Stuart Pocock, Lars Wilhelmsen, Kenneth Dickstein, Gary Francis and Janet Wittes .- Data Monitoring of a Placebo-controlled Trial of Daclizumab in Acute Graft-versus-Host Disease-David Zahrich, Stephanie J. Lee and David Harrington .- Introduction-David L. DeMets .- Clinical Trials of Herpes Simplex Encephalitis: The Role of the Data Monitoring Committee-Richard J. Whitley .- The Nocturnal Oxygen Therapy Trial Data Monitoring Experience - Problem with Reporting Lags-David L. DeMets, George W. Williams andByron W. Brown, Jr. .- The Cooperative North Scandinavian Enalapril Survival Study II Trial-Steven